Sun Pharma Q2 FY24 Results Today
Sun Pharma Q2 results show revenue up from 12,145.28 crores to 12,486.02 crores, a 2.81% increase in growth. EPS rose from ₹8.4 to ₹9.9, up by 17.86%.
Quarter-on-Quarter Basis Results (Q2 FY2024):
Sun Pharma shared its Q2 results on Wednesday. They earned 12,486.02 crores in revenue this quarter, but that’s more than the 12,145.28 crores they made last quarter. The company’s growth increased by 2.81 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 2375.51 crores, up from 2022.54 crores in the previous quarter. Their quarter-to-quarter growth increased by 17.45 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹9.9, which is an increase of 17.86% from the ₹8.4 EPS in the previous quarter.
Year-over-Year Basis Results (Q2 FY2024):
The company made a total revenue of 12,486.02 crores this year (2023), which is 13.12 percent higher than last year’s total revenue of 11,037.50 crores.
This year’s PAT (Profit After Tax) is 2375.51 crores, which is also 5.00% higher than last year’s PAT of 2262.22 crores.
The EPS (Earnings Per Share) for this year is ₹9.9, which is 5.32% more than the EPS of ₹9.4 earned last year.
Year-over-Year Basis Results (Half Year Ended FY2024):
In the first half of 2023, the company generated a total revenue of 24,631.30 crores, marking a 12.98% increase compared to the previous year’s 21,801.40 crores.
The PAT (Profit After Tax) for this half-year stands at 4398.05 crores, showing a 1.73% growth over the previous year’s 4323.10 crores.
The EPS (Earnings Per Share) for this half-year is ₹18.3, representing a 1.67% increase from the previous half-year’s EPS of ₹18.00.
Sun Pharma Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Sun Pharma:
Sun Pharma, which started from modest origins in 1983, has evolved into one of the leading global manufacturers of generic pharmaceuticals. It proudly holds the position of the largest pharmaceutical company in India and ranks among the top 10 generic pharmaceutical firms in the United States. Notably, Sun Pharma is the second-largest player in the generic dermatology market when measured by prescription volume.
Download the Full PDF of Q2 Results: Click Here
For more of the Latest News, Click Here